Post-transplant lymphoproliferative disorders: Molecular analysis of histogenesis and pathogenesis

Minerva Medica

Volumn 95, Issue 1, 2004, Pages 53-64

  Capello, D ^a   Berra, E ^a   Cerri, M ^a   Gaidano, G ^a  

^a UNIVERSITY OF EASTERN PIEDMONT   (Italy)

Author keywords

Lymphoma, genetics; Lymphoma, physiopathology; Lymphoproliferative disorders; Organ transplantation

Indexed keywords

PROTEIN; PROTEIN BCL 6; PROTEIN MUM1; SYNDECAN 1; UNCLASSIFIED DRUG;

ADOLESCENT; ADULT; AGED; APOPTOSIS; ARTICLE; B LYMPHOCYTE DIFFERENTIATION; CARCINOGENESIS; CHILD; CLINICAL FEATURE; CONTROLLED STUDY; DISEASE CLASSIFICATION; DNA METHYLATION; EPSTEIN BARR VIRUS; FEMALE; GENE DELETION; GENE MUTATION; GENE REARRANGEMENT; GENETICS; GERMINAL CENTER; HISTOGENESIS; HUMAN; HUMAN TISSUE; IMMUNOGLOBULIN VARIABLE REGION; IMMUNOHISTOCHEMISTRY; IMMUNOPHENOTYPING; LYMPHOMA; LYMPHOPROLIFERATIVE DISEASE; MAJOR CLINICAL STUDY; MALE; MORPHOLOGY; ORGAN TRANSPLANTATION; PATHOGENESIS; PATHOPHYSIOLOGY; POLYMERASE CHAIN REACTION; PROGNOSIS; PROTEIN EXPRESSION;

ADOLESCENT; ADULT; AGED; B-LYMPHOCYTES; CELL DIFFERENTIATION; CELL TRANSFORMATION, VIRAL; CHILD; CHILD, PRESCHOOL; EPSTEIN-BARR VIRUS INFECTIONS; FEMALE; GENE REARRANGEMENT, B-LYMPHOCYTE; GENES, IMMUNOGLOBULIN; HERPESVIRUS 4, HUMAN; HUMANS; INFANT; LYMPHOMA, B-CELL; LYMPHOPROLIFERATIVE DISORDERS; MALE; MIDDLE AGED; ORGAN TRANSPLANTATION; PHENOTYPE;

EID: 2442668957     PISSN: 00264806     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (45)

1. Penn I, Hammon W, Brettscneider L, Starzl TE. Malignant lymphoma in transplantation patients. Transplant Proc 1969;1:106-12.
2. Greiner T, Armitage JO, Gross TG. Atypical lymphoproliferative diseases. Hematology (Am Soc Hematol Educ Program) 2000:133-46.
3. Harris N, Swerdlow S, Frizzera G, Knowles D. Posttransplant lymphoproliferative disorders. Lyon: IARC Press; 2001.
4. Jaffe ES, Harris NL, Stein H, Vardiman JW. World Health Organization Classification of Tumours. Pathology and Genetics. Tumours of haematopoietic and lymphoid tissues. Lyon: IARC Press; 2001.
5. Locker J, Nalesnik M. Molecular genetic analysis of lymphoid tumors arising after organ transplantation. Am J Pathol 1989;135:977-87.
6. Knowles DM, Cesarman E, Chadburn A, Frizzera G, Chen J, Rose EA et al: Correlative morphologic and molecular genetic analysis demonstrates three distinct categories of posttransplantation lymphoproliferative disorders. Blood 1995;85:552-65.
7. Leblond V, Davi F, Charlotte F, Dorent R, Bitker MO, Sutton L et al. Posttransplant lymphoproliferative disorders not associated with Epstein-Barr virus: a distinct entity? J Clin Oncol 1998;16:2052-9.
8. Dotti G, Fiocchi R, Motta T, Gamba A, Gotti E, Gridelli B et al. Epstein-Barr virus negative lymphoproliferative disorders in long-term survivors after heart, kidney, and liver transplant. Transplantation 2000;69:827-33.
9. Swinnen LJ. Transplantation-related lymphoproliferative disorder: a model for human immunodeficiency virus-related lymphomas. Semin Oncol 2000;27:402-8.
10. Muti G, Cantoni S, Oreste P, Klersy C, Gini G, Rossi V et al. Post-transplant lympoproliferative disorders: improved outcome after clinico-pathologically tailored treatment. Haematologica 2002;87:67-77.
11. Müller-Hermelink HK, Greiner A. Molecular analysis of human immunoglobulin heavy chain variable genes (IgVH) in normal and malignant B cells. Am J Pathol 1998;153:1341-6.
12. Küppers R, Klein U, Hansmann ML, Rajewsky K. Cellular origin of human B-cell lymphomas. N Engl J Med 1999;341:1520-9.
13. Stevenson FK, Sahota SS, Ottensmeier CH, Zhu D, Forconi F, Hamblin TJ. The occurrence and significance of V gene mutations in B cell-derived human malignancy. Adv Cancer Res 2001;83:81-116.
14. Cattoretti G, Chang C-C, Cechova C, Zhang J, Ye BH, Falini B et al. BCL-6 protein is expressed in germinal-center B cells. Blood 1995;86:45-53.
15. Falini B, Fizzotti M, Pucciarini A, Bigerna B, Marafioti T, Gambacorta M et al. A monoclonal antibody (MUM1p) detects expression of the MUM1/IRF4 protein in a subset of germinal center B cells, plasma cells, and activated T cells. Blood 2000;95:2084-92.
16. Carbone A, Gloghini A, Larocca LM, Capello D, Pierconti F, Canzonieri V et al. Expression profile of MUM1/IRF-4, BCL-6, and CD138/syndecan-1 defines novel histogenetic subsets of human immunodeficiency virus-related lymphomas. Blood 2001;97:744-51.
17. Singal R, Ginder GD. DNA methylation. Blood 1999;93:4059-70.
18. Robertson KD. DNA methylation, methyltransferases, and cancer. Oncogene 2001;20:3139-55.
19. Baur AS, Shaw P, Burri N, Delacretaz F, Bosman FT, Chaubert P. Frequent methylation silencing of p15(INK4b) (MTS2) and p16(INK4a) (MTS1) in B-cell and T-cell lymphomas. Blood 1999;94:1773-81.
20. Esteller M, Gaidano G, Goodman SN, Zagonel V, Capello D, Botto B et al. Hypermethylation of the DNA repair gene O(6)-methylguanine DNA methyltransferase and survival of patients with diffuse large B-cell lymphoma. J Natl Cancer Inst 2002;94:26-32.
21. Katzenellenbogen RA, Baylin SB, Herman JG. Hypermethylation of the DAP-kinase CpG island is a common alteration in B-cell malignancies. Blood 1999;93:4347-53.
22. Cohen O, Inbal B, Kissil JL, Raveh T, Berissi H, Spivak-Kroizaman T et al. DAP-kinase participates in TNF-alpha- and Fas-induced apoptosis and its function requires the death domain. J Cell Biol 1999;146:141-8.
23. Raveh T, Droguett G, Horwitz MS, DePinho RA, Kimchi A. DAP kinase activates a p19ARF/p53-mediated apoptotic checkpoint to suppress oncogenic transformation. Nat Cell Biol 2001;3:1-7.
24. Jenkins PJ, Farrel PJ. Are particular Epstein-Barr virus strains linked to disease? Semin Cancer Biol 1996;7:209-15.
25. Munch M. Epstein-Barr virus strain characterization. APMIS 1998;106:425-33.
26. Gratama JW, Ernberg I. Molecular epidemiology of Epstein-Barr virus infection. Adv Cancer Res 1995;67:197-225.
27. Yao QY, Croom-Carter DSG, Tierney RJ, Habeshaw G, Wilde JT, Hill FGH et al. Epidemiology of infection with Epstein-Barr virus types 1 and 2: lessons from the study of a T-cell-immunocompromised hemophilic cohort. J Virol 1998;72:4352-63.
28. Wang D, Liebowitz D, Kieff E. An EBV membrane protein expressed in immortalized lymphocytes transforms established rodent cells. Cell 1985;43:831-40.
29. Chen M. Tsai CN, Liang CL, Shu CH, Huang CR, Sulitzeanu D et al. Cloning and characterization of the latent membrane protein (LMP) of a specific Epstein-Barr virus variant derived from the nasopharingeal carcinoma in the Taiwanese population. Oncogene 1992;7:2131-40.
30. Knecht H, Bachmann E, Brousset P, Sandvej K, Nadal D, Bachmann F et al. Deletions within the LMP-1 oncogene of Epstein-Barr virus are clustered in Hodgkin's disease and identical to those observed in nasopharingeal carcinoma. Blood 1993;82:2937-42.
31. Dolcetti R, Quaia M, Gloghini A, De Re V, Zancai P, Cariati R et al. Biologically relevant phenotypic changes and enhanced growth properties induced in B lymphocytes by an EBV strain derived from a histologically aggressive Hodgkin's disease. Int J Cancer 1999;80:240-9.
32. Fais F, Ghiotto F, Hashimoto S, Sellars B, Valetto A, Ilen SL et al. Chronic lymphocytic leukaemia B cells express restricted sets of mutated and unmutated antigen receptors. J Clin Invest 1998;102:1515-25.
33. Fais F, Gaidano G, Capello D, Gloghini A, Ghiotto F, Rondella S et al. Immunoglobulin V region gene use and structure suggest antigen selection in AIDS-related primary effusion lymphomas. Leukemia 1999;13:1093-9.
34. Küppers R, Zhao M, Hansmann M-L, Rajewsky K. Tracing B cell development in human germinal centres by molecular analysis of single cells picked from histological sections. EMBO J 1993;12:4955-67.
35. Capello D, Vitolo U, Pasqualucci L, Quattrone S, Migliaretti G, Fassone L et al. Distribution and pattern of BCL-6 mutations throughout the spectrum of B-cell neoplasia. Blood 2000;95:651-9.
36. Farner NL, Dörner T, Lipsky PE. Molecular mechanisms and selection influence the generation of the human VλJλ repertoire. J Immunol 1999;162:2137-45.
37. Kingma DW, Weiss WB, Jaffe ES, Kumar S, Frekko K, Raffeld M. Epstein-Barr virus latent membrane protein-1 oncogene deletions: correlations with malignancy in Epstein-Barr virus-associated lymphoproliferative disorders and malignant lymphomas. Blood 1996;88:242-51.
38. Klein C, Rothenberger S, Niemeyer C, Bachmann E, Odermatt B, Bohm N et al. EBV-associated lymphoproliferative syndrome with a distinct 69 base-pair deletion in the LMP-1 oncogene. Br J Haematol 1995;91:938-40.
39. Khanim F, Yao Q-YY, Niedobitek G, Sihota S, Rickinson AB, Young LS. Analysis of Epstein-Barr virus gene polymorphisms in normal donors and in virus-associated tumors from different geographic locations. Blood 1996;88:3491-501.
40. Armitage JM, Kormos RL, Stuart RS. Post-transplant lymphoproliferative disease in thoracic organ transplant patients: ten years of cyclosporine-based immunosuppressin. J Heart Lung Transplant 1991;10:877-87.
41. Brezinschek H-P, Foster SJ, Brezinschek RI, Dörner T, Domiati-Saad R, Lipsky PE. Analysis of the human VH gene repertoire. J Clin Invest 1997;99:2488-501.
42. Gaidano G, Cerri M, Capello D, Berra E, Deambrogi C, Rossi D et al. Molecular histogenesis of plasmablastic lymphoma of the oral cavity. Br J Haematol 2002;119:622-8.
43. Kitada S, Pedersen IM, Schimmer AD, Reed JC. Dysregulation of apoptosis genes in hematopoietic malignancies. Oncogene 2002;21:3459-74.
44. Barozzi P, Luppi M, Cagossi K, Majorana A, Marasca R, Artusi T et al. The oncogenic 30 and 69 bp deletion variants of the EBV LMP-1 gene are common in HIV-negative lymphoproliferations, both malignant and benign. Ann Oncol 1999;10:467-9.
45. Fassone L, Cingolani A, Martini M, Migliaretti G, Oreste PL, Capello D et al. Characterization of Epstein-Barr virus genotype in AIDS-related non-Hodgkin's lymphoma. AIDS Res Hum Retrov 2002;18:19-26.